Price movement over the last 24 hours
AdaptHealth Corp vs Deere & Company — how do they compare? AdaptHealth Corp trades at $10.02 (market cap $1.38B), while Deere & Company trades at $593.62 (market cap $162.94B). The key difference: Deere & Company is far larger — about 118.1× AdaptHealth Corp's market cap, and Deere & Company pays a 1.07% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | DE | |
|---|---|---|
Market Cap | $1.38B | $162.94B |
Sector | Health | Industrials |
52-Week High | $13.38 | $662.49 |
52-Week Low | $8.68 | $439.11 |
Enterprise Value | $3.33B | $217.76B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Deere & Company (DE) trades at $603.61, down 2.84% on the day, with the stock showing strong technical momentum despite recent volatility. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $6.55 exceeding estimates by 15%. Fundamentals remain solid with 10.33% net margins and 18.51% ROE, though revenue declined to $44.67B in 2025. Analyst consensus points to 39% buy ratings with a $666.08 price target, representing 10% upside potential.
DE presents a mixed outlook with strong operational execution offset by cyclical headwinds in agricultural equipment demand. The precision agriculture platform offers growth potential, but investors face risks from economic sensitivity and margin pressure. Current valuation at 36x P/E appears elevated relative to historical norms, requiring continued earnings growth to justify premium pricing.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →